IBDEI0VI ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,14028,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14028,1,3,0)
 ;;=3^Edema,Unspec
 ;;^UTILITY(U,$J,358.3,14028,1,4,0)
 ;;=4^R60.9
 ;;^UTILITY(U,$J,358.3,14028,2)
 ;;=^5019534
 ;;^UTILITY(U,$J,358.3,14029,0)
 ;;=M72.9^^83^821^33
 ;;^UTILITY(U,$J,358.3,14029,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14029,1,3,0)
 ;;=3^Fibroblastic Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,14029,1,4,0)
 ;;=4^M72.9
 ;;^UTILITY(U,$J,358.3,14029,2)
 ;;=^5013237
 ;;^UTILITY(U,$J,358.3,14030,0)
 ;;=M79.7^^83^821^34
 ;;^UTILITY(U,$J,358.3,14030,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14030,1,3,0)
 ;;=3^Fibromyalgia
 ;;^UTILITY(U,$J,358.3,14030,1,4,0)
 ;;=4^M79.7
 ;;^UTILITY(U,$J,358.3,14030,2)
 ;;=^46261
 ;;^UTILITY(U,$J,358.3,14031,0)
 ;;=M84.50XA^^83^821^36
 ;;^UTILITY(U,$J,358.3,14031,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14031,1,3,0)
 ;;=3^Fx in Neoplastic Disease,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,14031,1,4,0)
 ;;=4^M84.50XA
 ;;^UTILITY(U,$J,358.3,14031,2)
 ;;=^5014022
 ;;^UTILITY(U,$J,358.3,14032,0)
 ;;=M84.50XD^^83^821^39
 ;;^UTILITY(U,$J,358.3,14032,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14032,1,3,0)
 ;;=3^Fx in Neoplastic Disease,Unspec Site,Routine Healing
 ;;^UTILITY(U,$J,358.3,14032,1,4,0)
 ;;=4^M84.50XD
 ;;^UTILITY(U,$J,358.3,14032,2)
 ;;=^5014023
 ;;^UTILITY(U,$J,358.3,14033,0)
 ;;=M84.50XS^^83^821^40
 ;;^UTILITY(U,$J,358.3,14033,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14033,1,3,0)
 ;;=3^Fx in Neoplastic Disease,Unspec Site,Sequela
 ;;^UTILITY(U,$J,358.3,14033,1,4,0)
 ;;=4^M84.50XS
 ;;^UTILITY(U,$J,358.3,14033,2)
 ;;=^5014027
 ;;^UTILITY(U,$J,358.3,14034,0)
 ;;=M84.50XG^^83^821^35
 ;;^UTILITY(U,$J,358.3,14034,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14034,1,3,0)
 ;;=3^Fx in Neoplastic Disease,Unspec Site,Delayed Healing
 ;;^UTILITY(U,$J,358.3,14034,1,4,0)
 ;;=4^M84.50XG
 ;;^UTILITY(U,$J,358.3,14034,2)
 ;;=^5014024
 ;;^UTILITY(U,$J,358.3,14035,0)
 ;;=M84.50XK^^83^821^38
 ;;^UTILITY(U,$J,358.3,14035,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14035,1,3,0)
 ;;=3^Fx in Neoplastic Disease,Unspec Site,Nonunion
 ;;^UTILITY(U,$J,358.3,14035,1,4,0)
 ;;=4^M84.50XK
 ;;^UTILITY(U,$J,358.3,14035,2)
 ;;=^5014025
 ;;^UTILITY(U,$J,358.3,14036,0)
 ;;=M84.50XP^^83^821^37
 ;;^UTILITY(U,$J,358.3,14036,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14036,1,3,0)
 ;;=3^Fx in Neoplastic Disease,Unspec Site,Malunion
 ;;^UTILITY(U,$J,358.3,14036,1,4,0)
 ;;=4^M84.50XP
 ;;^UTILITY(U,$J,358.3,14036,2)
 ;;=^5014026
 ;;^UTILITY(U,$J,358.3,14037,0)
 ;;=M84.60XA^^83^821^42
 ;;^UTILITY(U,$J,358.3,14037,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14037,1,3,0)
 ;;=3^Fx in Oth Disease,Unspec Site,Init Encntr
 ;;^UTILITY(U,$J,358.3,14037,1,4,0)
 ;;=4^M84.60XA
 ;;^UTILITY(U,$J,358.3,14037,2)
 ;;=^5014214
 ;;^UTILITY(U,$J,358.3,14038,0)
 ;;=M84.60XD^^83^821^45
 ;;^UTILITY(U,$J,358.3,14038,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14038,1,3,0)
 ;;=3^Fx in Oth Disease,Unspec Site,Rountine Healing
 ;;^UTILITY(U,$J,358.3,14038,1,4,0)
 ;;=4^M84.60XD
 ;;^UTILITY(U,$J,358.3,14038,2)
 ;;=^5014215
 ;;^UTILITY(U,$J,358.3,14039,0)
 ;;=M84.60XS^^83^821^46
 ;;^UTILITY(U,$J,358.3,14039,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,14039,1,3,0)
 ;;=3^Fx in Oth Disease,Unspec Site,Sequela
 ;;^UTILITY(U,$J,358.3,14039,1,4,0)
 ;;=4^M84.60XS
 ;;^UTILITY(U,$J,358.3,14039,2)
 ;;=^5014219
 ;;^UTILITY(U,$J,358.3,14040,0)
 ;;=M84.60XG^^83^821^41
